UK agency nearer backing new breast cancer drugs

	Tweet

Britain’s cost-effectiveness watchdog NICE came one step closer on Friday to approving a new class of breast cancer treatments known as aromatase inhibitors.

The decision by the National Institute of Health and Clinical Excellence (NICE) to proceed to its final appraisal means drugs made by the likes of AstraZeneca, Swiss drugmaker Norvatis and Pfizer Inc. could soon be freely available to patients on the country’s National Health Service.

NICE said its appraisals committee had prepared a final report and sent it to the institute. 

NICE, which is responsible for deciding which medicines are paid for on the NHS, said there was now a 15-day appeal period.

“Subject to any appeal by consultees, the (final appraisal) may be used as the basis for the institute’s guidance on the use of the appraised technology in the NHS in England and Wales,” the appraisal committee said.

Aromatase inhibitors have been shown in clinical trials to give greater protection than tamoxifen against the risk of breast cancer returning after surgery. Tamoxifen has been used to treat breast cancer for decades.

“This milestone brings us close to ending the postcode lottery for AIs, such as anastrozole, which has been shown to significantly improve women’s chances of surviving early breast cancer over and above the benefit seen with tamoxifen,” said Professor Jeffrey Tobias of London’s University College.

“This recommendation brings the UK in line with some other European countries, where AIs have now become the new gold standard treatment for early breast cancer,” said Tobias, professor of cancer medicine at the university.

AstraZeneca, Novartis and Pfizer make Arimidex, Femara and Aromasin respectively. Their drugs chemical names are respectively known as anastrozole, letrozole and exemestane.

Around 41,000 women in the UK are diagnosed with breast cancer each year, and an estimated 60 percent of these have tumours that would be eligible for treatment with AIs.

RELATED STORIES:
Online Information May Improve Cancer Patients’ Opinions About Doctors   Long-term hormone replacement therapy increases breast cancer risk   Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment   Many breast cancer patients take high doses of antioxidants despite possible consequences   New role discovered for breast cancer susceptibility gene BRCA1   Nicotine in cigarettes linked to breast cancer for the first time   Cosmetic Breast Implants Do Not Interfere With Detecting Breast Cancer   Virus kills breast cancer cells in laboratory   A New Way to Study How Breast Cancer Spreads   Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers   Breast cancer milieu—Progression, tamoxifen sensitivity, and DNA reversion   New Clues to Breast Cancer Development in High-Risk Women   Scientists Discover Cell Pathway that Drives a Deadly Sub-Type of Breast Cancer   Blood thinners like aspirin may fight cancer: study   Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer   Fruits, veggies slash breast cancer risk: U.S. study   Genes linked to spread of breast cancer discovered   Clues to Pregnancy-Associated Breast Cancer Found   Another step toward resisting breast cancer   Many Women Who Had Childhood Cancer Do Not Undergo Breast Cancer Screening   Intake of Vitamin D, Calcium Associated With Lower Risk of Breast Cancer Before Menopause   Mammography May Be Beneficial To All Women, Regardless of Age

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]